Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline

NMRA•2026-07-27

Preclinical NMRA-215 data showed weight loss

Preclinical NMRA-215 data showed up to 19% weight loss as monotherapy; up to 26% when combined with semaglutide.

Corporate presentation highlights three lead programs

Neumora outlined three lead programs across cardiometabolic, neurodegenerative, and neuropsychiatric disease, anchored by NMRA-215, NMRA-511, and NMRA-898.

NMRA-215: NLRP3 inhibitor in obesity/CV risk. IND submission targeted for 4Q 2026; Phase 1 start planned by year-end 2026.
NMRA-511: V1aR antagonist for agitation in Alzheimer’s disease. Multiple-ascending-dose extension data expected 4Q 2026; Phase 2 initiation planned by year-end 2026.
NMRA-898: M4 modulator for schizophrenia. Phase 1 data expected in 2H 2026.

Sources

Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline

Docs

Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline

Preclinical NMRA-215 data showed weight loss

Corporate presentation highlights three lead programs

Related News

D-Wave rises after AT&T expands quantum computing partnership

Enterprise Financial Services Corp <EFSC.O>: Raymond James Raises Target Price to $73 From $72

Frequency Electronics Inc. Announces Space Mission Contract Award Valued At Approximately $8 Million

Sources

Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline

NextEra Energy Inc <NEE.N>: Bernstein Raises Target Price to $108 From $107

Verizon <VZ.N>: Bernstein Raises Target Price to $47 From $44